Results 231 to 240 of about 209,693 (354)

NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer

open access: yesAdvanced Science, EarlyView.
Multi‐omic profiling of T1 high‐grade bladder cancer identifies a high‐risk subtype (T1HG1) driven by NQO1, which couples anoikis resistance with immune evasion. NQO1 orchestrates macrophage–T cell crosstalk suppression via CXCL9 modulation. Pharmacological NQO1 inhibition with skullcapflavone II enhances cisplatin efficacy, representing a promising ...
Bin Guo   +20 more
wiley   +1 more source

Generation of effector cells from T cell subsets [PDF]

open access: yes, 1979
Koszinowski, Ulrich H., Simon, M. M.
core  

Transcriptomic and Neuroimaging Decoding of Brain‐Immune Crosstalk in Thyroid Eye Disease

open access: yesAdvanced Science, EarlyView.
This study employed an imaging transcriptomics framework integrating resting‐state fMRI with Allen Human Brain Atlas transcriptomic data, coupled with peripheral blood RNA sequencing, to decode brain‐immune crosstalk in thyroid eye disease. Frontal, parietal, subcortical, and brainstem regions were identified as key neuroimmune‐ vulnerable regions ...
Haiyang Zhang   +15 more
wiley   +1 more source

Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
Engineered mesoporous silica nanoparticles (Silicasomes) enable systemic delivery of the STING agonist ADU‐S100, overcoming the instability and toxicity that limit cyclic dinucleotides to local administration. By enhancing tumor accumulation, activating systemic antitumor immunity, and remodeling the tumor immune microenvironment, these nanoparticles ...
Wenjing Zhou   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy